TMO · Thermo Fisher Scientific Inc.
$513.032026-07-21Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
Base · active
$124
-75.7% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($101 · $177) Analysts Range ($490 · $683) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $42.9B | — | 17.4% | 8.0% | $6.9B | $1.3B | $8.1B | 7.6% | — | 9.3% | $73.9B | $16.07 | — |
| 2024.Q4 | $42.9B | 0.0% | 17.4% | 9.4% | $6.7B | −$1.8B | $5.0B | 8.7% | — | 9.0% | $75.5B | $16.07 | — |
| 2025.Q1 | $42.9B | 0.1% | 17.9% | 6.8% | $7.1B | −$2.5B | $4.6B | 8.7% | — | 9.3% | $77.6B | $16.98 | — |
| 2025.Q4 | $42.9B | 0.0% | 17.9% | 7.5% | $7.1B | −$2.3B | $4.8B | 8.7% | — | 8.8% | $83.0B | $16.98 | — |
| 2026.Q1 | $45.2B | 5.4% | 17.8% | 7.1% | $7.5B | −$10.8B | −$3.3B | 8.3% | — | 8.5% | $91.8B | $18.39 | 23.8 |
| italics below = DCF projection · 10yr Rev CAGR: 5% |
| 2027.Q1 | $48.4B | +7.1% | 18.3% | 8.3% | $8.1B | −$6.9B | $1.2B | 9.1% | $1.1B | 8.5% | $98.7B | $21.78 | 23.6 |
| 2028.Q1 | $51.1B | +5.6% | 18.9% | 9.7% | $8.7B | −$5.7B | $3.0B | 9.0% | $2.5B | 8.6% | $104.5B | $23.43 | 21.9 |
| 2029.Q1 | $54.2B | +6.1% | 19.7% | 10.9% | $9.5B | −$6.4B | $3.1B | 9.0% | $2.4B | 8.8% | $110.9B | $25.55 | 20.1 |
| 2030.Q1 | $56.9B | +4.9% | 21.3% | 12.2% | $10.7B | −$5.6B | $5.1B | 8.9% | $3.6B | 9.4% | $116.5B | $28.56 | 18.0 |
| 2031.Q1 | $59.6B | +4.8% | 21.3% | 13.5% | $11.0B | −$5.7B | $5.3B | 8.9% | $3.4B | 9.2% | $122.2B | $29.48 | 17.4 |
|
| Term. Yr+ | $76.9B | 4.1% | 19.6% | 20.0% | $12.0B | −$5.7B | $6.3B | 8.6% | $59.8B | 8.6% | — | — | — |
Active scenario IV: $124 (-75.7% vs market)